Literature DB >> 16812966

Premenopausal women and low bone density.

Aliya Khan1.   

Abstract

OBJECTIVE: To review the evidence and provide an approach to management of low bone density among premenopausal women. QUALITY OF EVIDENCE MEDLINE: was searched from January 1990 to November 2004 and articles graded by level of evidence (I to III). Diagnosis and management recommendations were based on evidence from randomized controlled trials and expert consensus. MAIN MESSAGE: Bone mineral density (BMD) testing among premenopausal women should be completed only in the presence of approved indications. Current evidence does not support screening for osteoporosis among premenopausal women. Low BMD in premenopausal women is associated with a lower fracture risk than seen in postmenopausal women. In the absence of fragility fractures, low BMD might reflect low peak bone mass based on genetic predisposition, environment, and lifestyle factors. Clinical evaluation enables distinction between low peak bone mass and a systemic disorder resulting in low BMD and skeletal fragility. Common causes of low bone density among premenopausal women include ovulatory disturbances and low body weight.
CONCLUSION: Bone mineral density alone is insufficient for diagnosis of osteoporosis among premenopausal women in the absence of fragility fractures. Antiresorptive therapy has been evaluated and shown to benefit premenopausal women using glucocorticoid therapy or those with primary hyperparathyroidism.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16812966      PMCID: PMC1780157     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN: 0008-350X            Impact factor:   3.275


  28 in total

Review 1.  Low-dose oral contraceptives and bone mineral density: an evidence-based analysis.

Authors:  W Kuohung; L Borgatta; P Stubblefield
Journal:  Contraception       Date:  2000-02       Impact factor: 3.375

2.  Changes in bone mineral density with age in men and women: a longitudinal study.

Authors:  L Warming; C Hassager; C Christiansen
Journal:  Osteoporos Int       Date:  2002       Impact factor: 4.507

3.  Effects of contraceptive use on bone biochemical markers in young women.

Authors:  S M Ott; D Scholes; A Z LaCroix; L E Ichikawa; C K Yoshida; W E Barlow
Journal:  J Clin Endocrinol Metab       Date:  2001-01       Impact factor: 5.958

4.  Fractures before menopause: a red flag for physicians.

Authors:  W D Hosmer; H K Genant; W S Browner
Journal:  Osteoporos Int       Date:  2002       Impact factor: 4.507

5.  Oral contraceptive use and bone mineral density in premenopausal women: cross-sectional, population-based data from the Canadian Multicentre Osteoporosis Study.

Authors:  J C Prior; S A Kirkland; L Joseph; N Kreiger; T M Murray; D A Hanley; J D Adachi; Y M Vigna; C Berger; L Blondeau; S A Jackson; A Tenenhouse
Journal:  CMAJ       Date:  2001-10-16       Impact factor: 8.262

Review 6.  2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada.

Authors:  Jacques P Brown; Robert G Josse
Journal:  CMAJ       Date:  2002-11-12       Impact factor: 8.262

7.  Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial.

Authors:  J D Adachi; K G Saag; P D Delmas; U A Liberman; R D Emkey; E Seeman; N E Lane; J M Kaufman; P E Poubelle; F Hawkins; R Correa-Rotter; C J Menkes; J A Rodriguez-Portales; T J Schnitzer; J A Block; J Wing; H H McIlwain; R Westhovens; J Brown; J A Melo-Gomes; B L Gruber; M J Yanover; M O Leite; K G Siminoski; M C Nevitt; J T Sharp; M P Malice; T Dumortier; M Czachur; W Carofano; A Daifotis
Journal:  Arthritis Rheum       Date:  2001-01

8.  Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study.

Authors:  D M Reid; R A Hughes; R F Laan; N A Sacco-Gibson; D H Wenderoth; S Adami; R A Eusebio; J P Devogelaer
Journal:  J Bone Miner Res       Date:  2000-06       Impact factor: 6.741

9.  Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy.

Authors:  S Wallach; S Cohen; D M Reid; R A Hughes; D J Hosking; R F Laan; S M Doherty; M Maricic; C Rosen; J Brown; I Barton; A A Chines
Journal:  Calcif Tissue Int       Date:  2000-10       Impact factor: 4.333

10.  Bone mineral density at various anatomic bone sites in women receiving combined oral contraceptives and depot-medroxyprogesterone acetate for contraception.

Authors:  P Wanichsetakul; A Kamudhamas; P Watanaruangkovit; Y Siripakarn; P Visutakul
Journal:  Contraception       Date:  2002-06       Impact factor: 3.375

View more
  12 in total

1.  What is adequate?

Authors:  Adrian B Jones
Journal:  Can Fam Physician       Date:  2006-09       Impact factor: 3.275

2.  Correlation between bone mineral density and body composition in Japanese females aged 18-40 years with low forearm bone mineral density.

Authors:  Misao Arimatsu; Takao Kitano; Naoko Kitano; Makoto Futatsuka
Journal:  Environ Health Prev Med       Date:  2008-11-11       Impact factor: 3.674

3.  Premenopausal women with idiopathic low-trauma fractures and/or low bone mineral density.

Authors:  A Cohen; R R Recker; J Lappe; D W Dempster; S Cremers; D J McMahon; E M Stein; J Fleischer; C J Rosen; H Rogers; R B Staron; J Lemaster; E Shane
Journal:  Osteoporos Int       Date:  2011-03-02       Impact factor: 4.507

4.  Predictors of bone mineral density in african-american and caucasian college-aged women.

Authors:  Andrea K Johnson; M Allison Ford; Tamekia L Jones; Vinayak K Nahar; Jeffrey S Hallam
Journal:  Health Promot Perspect       Date:  2015-03-29

Review 5.  Anorexia nervosa: COVID-19 pandemic period (Review).

Authors:  Mihai Cristian Dumitrașcu; Florica Șandru; Mara Carsote; Razvan Cosmin Petca; Ancuta Augustina Gheorghisan-Galateanu; Aida Petca; Ana Valea
Journal:  Exp Ther Med       Date:  2021-05-26       Impact factor: 2.447

6.  Clinical characteristics and medication use among premenopausal women with osteoporosis and low BMD: the experience of an osteoporosis referral center.

Authors:  Adi Cohen; Jessica Fleischer; Matthew J Freeby; Donald J McMahon; Dinaz Irani; Elizabeth Shane
Journal:  J Womens Health (Larchmt)       Date:  2009 Jan-Feb       Impact factor: 2.681

7.  Estrogen-related and other disease diagnoses preceding Parkinson's disease.

Authors:  Jeanne C Latourelle; Merete Dybdahl; Anita L Destefano; Richard H Myers; Timothy L Lash
Journal:  Clin Epidemiol       Date:  2010-08-09       Impact factor: 4.790

8.  Individual trabeculae segmentation (ITS)-based morphological analysis of high-resolution peripheral quantitative computed tomography images detects abnormal trabecular plate and rod microarchitecture in premenopausal women with idiopathic osteoporosis.

Authors:  X Sherry Liu; Adi Cohen; Elizabeth Shane; Emily Stein; Halley Rogers; Shannon L Kokolus; Perry T Yin; Donald J McMahon; Joan M Lappe; Robert R Recker; X Edward Guo
Journal:  J Bone Miner Res       Date:  2010-07       Impact factor: 6.741

9.  Updated recommendations for the diagnosis and management of osteoporosis: a local perspective.

Authors:  Hussein Raef; Munira Al-Bugami; Sakra Balharith; Mahmoud Moawad; Mohammad El-Shaker; Anita Hassan; Ahmad Al-Shaikh; Ismail Al-Badawi
Journal:  Ann Saudi Med       Date:  2011 Mar-Apr       Impact factor: 1.526

10.  Prevalence of osteoporosis in the Italian population and main risk factors: results of BoneTour Campaign.

Authors:  Loredana Cavalli; Andrea Guazzini; Luisella Cianferotti; Simone Parri; Tiziana Cavalli; Alessia Metozzi; Francesca Giusti; Caterina Fossi; Dennis M Black; Maria Luisa Brandi
Journal:  BMC Musculoskelet Disord       Date:  2016-09-17       Impact factor: 2.362

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.